(NOVO-B) Novo Nordisk - Performance -53.2% in 12m
NOVO-B performance: live returns, drawdowns, peer ranking & SPY comparison from 1w to 5y, all in one clean chart-driven dashboard.
Performance Rating
42.41%
#11 in Peer-Group
Rel. Strength
8.04%
#7080 in Stock-Universe
Total Return 12m
-53.19%
#140 in Peer-Group
Total Return 5y
120.20%
#12 in Peer-Group
| P/E | Value |
|---|---|
| P/E Trailing | 18.4 |
| P/E Forward | 16.6 |
| High / Low | DKK |
|---|---|
| 52 Week High | 964.69 DKK |
| 52 Week Low | 390.00 DKK |
| Sentiment | Value |
|---|---|
| VRO Trend Strength +-100 | 41.86 |
| Buy/Sell Signal +-5 | -0.66 |
| Support / Resistance | Levels |
|---|---|
| Support | |
| Resistance |
12m Total Return: NOVO-B (-53.2%) vs XBI (-6.9%)
5y Drawdown (Underwater) Chart
Top Performer in Biotechnology
Overall best picks of Peer Group - Selected by proven GARP Predictive Metrics, sorted by Growth Rating
| Symbol | 1m | 12m | 5y | P/E | P/E Forward | PEG | EPS Stability | EPS CAGR |
|---|---|---|---|---|---|---|---|---|
| GILD NASDAQ Gilead Sciences |
0.92% | 72.5% | 80.4% | 23.5 | 14.1 | 0.23 | 28.3% | -3.71% |
| UTHR NASDAQ United Therapeutics |
-8.48% | -6.85% | 159% | 11.3 | 10.5 | 1.43 | 74.6% | 16.1% |
| AMGN NASDAQ Amgen |
2.26% | -3.11% | 38.6% | 27.2 | 14.2 | 0.99 | 0.60% | 41% |
| BIM PA Biomerieux |
-1.07% | 32.1% | -2.24% | 32.7 | 25.8 | 1.55 | -38.5% | -25.1% |
| NBIX NASDAQ Neurocrine Biosciences |
6.19% | -6.83% | 5.89% | 43 | 24.8 | 0.27 | 18.7% | -34.3% |
| KMDA NASDAQ Kamada |
12.6% | 39.2% | -5% | 27.6 | 22.4 | 0.9 | 68.9% | 36.8% |
| PTCT NASDAQ PTC Therapeutics |
-5.71% | 54.5% | -7.69% | 7.54 | 6.09 | 0.81 | - | 68% |
| ERF PA Eurofins Scientific SE |
1.98% | 29.3% | 17.2% | 28.9 | 15.4 | 0.64 | -62.1% | -19.3% |
Performance Comparison: NOVO-B vs XBI vs S&P 500
XBI (SPDR S&P Biotech ETF) is the Sector Benchmark for NOVO-B
| Total Return (including Dividends) | NOVO-B | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | -14.77% | 4.28% | 4.37% |
| 3 Months | 9.68% | 17.36% | 14.09% |
| 12 Months | -53.19% | -6.86% | 13.68% |
| 5 Years | 120.20% | -21.19% | 112.88% |
| Trend Score (consistency of price movement) | NOVO-B | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | -71.9% | 13.1% | 83.6% |
| 3 Months | 52.6% | 79.4% | 97.2% |
| 12 Months | -94.9% | -87.1% | 45.7% |
| 5 Years | 88.5% | -52.1% | 84% |
| Relative Strength (compared with Indexes) | Rank in Peer Group | vs. XBI | vs. S&P 500 |
|---|---|---|---|
| 1 Month | %th18.00 | -17.28% | -17.87% |
| 3 Month | %th32.50 | -6.54% | -3.86% |
| 12 Month | %th31.00 | -49.74% | -58.82% |
| 5 Years | %th94.50 | 179.43% | 3.44% |
FAQs
Does Novo Nordisk (NOVO-B) outperform the market?
No,
over the last 12 months NOVO-B made -53.19%, while its related Sector, the SPDR S&P Biotech (XBI) made -6.86%.
Over the last 3 months NOVO-B made 9.68%, while XBI made 17.36%.
Performance Comparison NOVO-B vs Indeces and Sectors
Above 0 means better perfomance compared to Symbol in this Timeframe
NOVO-B vs. Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | -0.2% | -19.1% | -36.9% | -67% |
| US NASDAQ 100 | QQQ | -0.6% | -19.7% | -38.7% | -66% |
| German DAX 40 | DAX | -2.9% | -16.4% | -49.8% | -87% |
| Shanghai Shenzhen CSI 300 | CSI 300 | -1% | -18.3% | -40.5% | -73% |
| Hongkong Hang Seng | HSI | 1.3% | -17.9% | -57.4% | -91% |
| India NIFTY 50 | INDA | 0.2% | -15.5% | -37.5% | -52% |
| Brasil Bovespa | EWZ | 2.9% | -18.6% | -55.2% | -57% |
NOVO-B vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | 0.7% | -18.6% | -41.1% | -77% |
| Consumer Discretionary | XLY | 0.8% | -17.4% | -28.4% | -69% |
| Consumer Staples | XLP | 2.1% | -14.5% | -35.9% | -61% |
| Energy | XLE | -1% | -21% | -30% | -56% |
| Financial | XLF | 0.8% | -17.9% | -40.3% | -81% |
| Health Care | XLV | 0.3% | -16.3% | -26.6% | -48% |
| Industrial | XLI | -0.8% | -18.6% | -43.6% | -79% |
| Materials | XLB | -0% | -19.2% | -40% | -60% |
| Real Estate | XLRE | 1.3% | -14.6% | -36.1% | -65% |
| Technology | XLK | -1.3% | -22.6% | -41.8% | -64% |
| Utilities | XLU | -0.5% | -17% | -38.7% | -76% |
| Aerospace & Defense | XAR | -1.4% | -19.5% | -55.5% | -103% |
| Biotech | XBI | -3.3% | -19.1% | -27% | -46% |
| Homebuilder | XHB | -0.9% | -24.1% | -31.8% | -61% |
| Retail | XRT | 0.3% | -16.8% | -30.7% | -64% |
NOVO-B vs. Commodities
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Oil | USO | -1.4% | -21.5% | -24.2% | -50% |
| Natural Gas | UNG | 8.3% | -0.5% | -5.9% | -43% |
| Gold | GLD | 1.6% | -14.4% | -51.9% | -93% |
| Silver | SLV | 1.1% | -13.6% | -48.3% | -71% |
| Copper | CPER | -6% | -26.6% | -56.3% | -74% |
NOVO-B vs. Bonds
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| iShares 20+ Years Bond | TLT | 1.1% | -16.9% | -32.7% | -51% |
| iShares High Yield Corp. Bond | HYG | 0.5% | -16.3% | -33.9% | -63% |